Piper Jaffray's Schimmer makes 2016 Sangamo HIV Prediction

• Joshua Schimmer of Piper Jaffray commented in a note that he is "eager to hit the reset button" within the biopharma sector.
• Schimmer presented a list of potential outcomes and events in 2016 which represent contrarian views or ones that investors "aren't even contemplating."
• The analyst noted some of his calls may be provocative and low-probability events.

It's been a "very long and tiring" year within the biotech sector, at least according to Joshua Schimmer of Piper Jaffray.

8. Sangamo Biosciences, Inc. SGMO 2.76%'s HIV program will prove to be a "black swan."
Schimmer suggested that investors may be "overlooking the upside potential" in Sangamo's HIV program as an out-licensing candidate. The analyst added that "tangible" progress on a partnership marks a "real potential source of upside" in the coming year.


Read more: http://www.benzinga.com/analyst-ratings/analyst-color/15/12/6060652/piper-jaffray-makes-15-provocative-predictions-for-bioph#ixzz3ugvTAVdH